For patients with elevated intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT)

Demonstrated safety profile

In a pooled analysis of 5 studies of preservative-containing or preservative-free tafluprost (ZIOPTAN)a

  • The incidence of conjunctival hyperemia ranged from 4% to 20% in a pooled analysis of 5 studies of preservative-containing or preservative-free tafluprost.

aPreservative-containing or preservative-free tafluprost was evaluated in 905 patients in 5 controlled studies of up to 24 months’ duration.

  • Nonocular adverse reactions reported at an incidence of 2% to 6% in these clinical studies in patients treated with ZIOPTAN were headache (6%), common cold (4%), cough (3%), and urinary tract infection (2%).
  • Low discontinuation rate: Approximately 1% of 905 patients discontinued ZIOPTAN due to ocular events across 5 trials of up to 24 months’ duration.

ZIOPTAN is indicated for reducing elevated IOP in patients with OAG or OHT.

Select Important Safety Information

ZIOPTAN has been reported to cause changes to pigmented tissues. The most frequently reported changes have been increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as ZIOPTAN is administered. After discontinuation of ZIOPTAN, pigmentation of the iris is likely to be permanent, while pigmentation of the periorbital tissue and eyelash changes have been reported to be reversible in some patients. Patients who receive treatment should be informed of the possibility of increased pigmentation. The long-term effects of increased pigmentation are not known. Iris color change may not be noticeable for several months to years. While treatment with ZIOPTAN can be continued in patients who develop noticeably increased iris pigmentation, these patients should be examined regularly.

ZIOPTAN may gradually change eyelashes and vellus hair in the treated eye. These changes include increased length, color, thickness, shape, and number of lashes. Eyelash changes are usually reversible on discontinuation of treatment.

Before prescribing ZIOPTAN, please read the Prescribing Information.